

## Electronic supplementary material

**ESM Table 1** Baseline characteristics of cohort of incident insulin users by insulin glargine exposure group: type 2 diabetic patients only

Characteristic	Data presented as	Non-glargine insulin	Non-glargine plus glargine insulin	Insulin glargine only	<i>p</i> value <sup>a</sup>
Subjects, <i>n</i> =12,852	% ( <i>n</i> )	79.8 (10,262)	5.4 (690)	14.8 (1900)	
Sex, % women	% ( <i>n</i> )	46.4 (4,761)	40.4 (279)	48.7 (926)	0.050
Age, years	median (LQ, UQ)	63 (54, 71)	58 (46, 69)	67 (58, 75)	<0.0001
BMI, kg/m <sup>2</sup>	mean (SD)	29.9 (6.3)	29.3 (6.9)	30.5 (6.3)	<0.0001
Systolic BP, mmHg	mean (SD)	137.7 (21.9)	135.3 (22.6)	139.8 (23.2)	0.070
Diastolic BP, mmHg	mean (SD)	76.8 (12.3)	77.6 (13.1)	77.8 (12.5)	<0.0001
HbA <sub>1c</sub> , %	mean (SD)	9.9 (2.1)	9.8 (2.2)	9.9 (1.9)	0.10
Duration of diabetes					
≥5 years	% ( <i>n</i> )	67.8 (6,962)	58.0 (400)	82.7 (1,571)	<0.0001
Age at diagnosis, years	median	55	50	57	0.0001
Prior cancer					
Ever	% ( <i>n</i> )	8.7 (894)	6.4 (44)	9.8 (187)	0.51
≤5 years ago	% ( <i>n</i> )	5.2 (530)	4.6 (32)	5.5 (105)	0.73
Prior CVD	% ( <i>n</i> )	39.6 (4,066)	30.0 (207)	40.3 (765)	<0.0001
Ever smoked	% ( <i>n</i> )	30.3 (2,391)	29.9 (159)	29.6 (370)	0.08
Use of oral glucose-lowering drugs at baseline <sup>b</sup>	% ( <i>n</i> )	89.0 (6,835)	89.8 (371)	97.6 (1,641)	<0.0001
In the two most deprived SIMD quintiles	% ( <i>n</i> )	47.5 (4,872)	39.4 (272)	49.5 (940)	<0.0001

<sup>a</sup>Age- and sex-adjusted *p* values are for tests of whether the overall variation between groups is significant and are taken from linear and logistic regressions of continuous and binary variables respectively

<sup>b</sup>Excludes 15% of patients in whom oral drug use at baseline was not known with certainty  
LQ, Lower quartile; UQ, upper quartile